Not much meat here, but at least it's popsitive:
>>CHAPEL HILL, N.C., Jan. 29 /PRNewswire-FirstCall/ -- POZEN Inc. (Nasdaq: POZN - news) announced today that the preliminary results of the company's first carcinogenicity study for its lead product candidate, MT 100, indicate that MT 100 is not carcinogenic in the test species, transgenic p53 mice. Results from the ongoing two-year rat carcinogenicity study will be available in 2003.
John R. Plachetka, Pharm.D., chairman, president and chief executive officer of POZEN, said, ``We are very pleased with these favorable preliminary data. As part of our ongoing dialogue with the FDA concerning this issue, we will submit the study report within the next few weeks.''
MT 100 is being developed as an oral, first-line treatment for migraine pain and associated symptoms. The effectiveness of the product candidate has been demonstrated in numerous Phase II and Phase III clinical studies involving thousands of patients. Last year the company announced that MT 100 provided comparable efficacy with fewer side effects when tested against Imitrex®, the worldwide market leader.<<
snip
Cheers, Tuck |
